Literature DB >> 10657412

Significant association of atrial vulnerability with atrial septal abnormalities in young patients with ischemic stroke of unknown cause.

K Berthet1, T Lavergne, A Cohen, L Guize, M G Bousser, J Y Le Heuzey, P Amarenco.   

Abstract

BACKGROUND AND
PURPOSE: Atrial septal abnormalities have been associated with cryptogenic ischemic stroke in young patients, but the causal link has not yet been established. Paradoxical embolism is considered the most likely mechanism but is rarely proven. It can be hypothesized that, in those patients, paroxysmal atrial arrhythmias, potentially favored by the anatomic abnormalities, can be another cause of thrombus formation and subsequent embolism to the brain. In this study we assessed the relationship between atrial vulnerability, reflecting arrhythmogenic properties of the atria, and atrial septal abnormalities in young patients with cryptogenic ischemic stroke.
METHODS: We enrolled 62 consecutive patients aged <55 years who had ischemic stroke of unknown cause and transesophageal echocardiography to assess atrial septal aneurysm (ASA) or patent foramen ovale (PFO) (ie, atrial septal abnormalities). These patients underwent electrophysiological study to measure atrial refractoriness and conduction time defining a vulnerability index (ie, latent atrial vulnerability) and to assess the inducibility of sustained (lasting >60 seconds) atrial fibrillation with the use of programmed atrial stimulation. Actual atrial vulnerability was defined by the presence of both latent vulnerability and inducibility of sustained atrial fibrillation lasting >60 seconds.
RESULTS: We found atrial vulnerability in 58% of patients with atrial septal abnormalities and in 25% of patients without (odds ratio=4.1 [95% CI, 1.3 to 12.7; P<0.02]). The difference between patients with and without PFO or between patients with both PFO and ASA and those without were also significant. Patients with inducible sustained atrial fibrillation had more frequent past history of palpitations and syncope than patients without (P<0.02).
CONCLUSIONS: Atrial vulnerability is associated with atrial septal abnormalities in patients with cryptogenic stroke. This result raises the question of the potential role of transient atrial arrhythmias in thrombus formation in the presence of PFO or ASA.

Entities:  

Mesh:

Year:  2000        PMID: 10657412     DOI: 10.1161/01.str.31.2.398

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  49 in total

1.  Cardiac Causes of Stroke.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-07       Impact factor: 3.598

2.  A neurosurgical presentation of patent foramen ovale with atrial septal aneurysm.

Authors:  Katie Walsh; Chandrasekaran Kaliaperumal; Gerry Wyse; George Kaar
Journal:  BMJ Case Rep       Date:  2011-07-20

Review 3.  Closure of patent foramen ovale: is the case really closed as well?

Authors:  F A Flachskampf; W G Daniel
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 4.  Patent foramen ovale and the risk of stroke: smoking gun guilty by association?

Authors:  P Amarenco
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

Review 5.  [Patent foramen ovale, atrial septum aneurysm, and stroke. An examination of the status of recent evidence].

Authors:  K Kraywinkel; M Jauss; H-C Diener; C Weimar
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

Review 6.  Is patent foramen ovale a modifiable risk factor for stroke recurrence?

Authors:  David M Kent; David E Thaler
Journal:  Stroke       Date:  2010-10       Impact factor: 7.914

Review 7.  Antithrombotic and interventional treatment options in cardioembolic transient ischaemic attack and ischaemic stroke.

Authors:  D J H McCabe; R D Rakhit
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01       Impact factor: 10.154

8.  Patent foramen ovale and stroke: prognosis and treatment in young adults.

Authors:  Steven C Cramer
Journal:  J Thromb Thrombolysis       Date:  2005-10       Impact factor: 2.300

9.  Interactions between cardiovascular and cerebrovascular disease.

Authors:  Giuseppe Di Pasquale; Stefano Urbinati; Enrica Perugini; Simona Gambetti
Journal:  Curr Treat Options Neurol       Date:  2012-12       Impact factor: 3.598

10.  Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

Authors:  Scott E Kasner; Balakumar Swaminathan; Pablo Lavados; Mukul Sharma; Keith Muir; Roland Veltkamp; Sebastian F Ameriso; Matthias Endres; Helmi Lutsep; Steven R Messé; J David Spence; Krassen Nedeltechev; Kanjana Perera; Gustavo Santo; Veronica Olavarria; Arne Lindgren; Shrikant Bangdiwala; Ashkan Shoamanesh; Scott D Berkowitz; Hardi Mundl; Stuart J Connolly; Robert G Hart
Journal:  Lancet Neurol       Date:  2018-09-28       Impact factor: 44.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.